Business Description
MediPharm Labs Corp
NAICS : 325412
SIC : 3741
ISIN : CA69354Q1090
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.02 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.63 | |||||
Beneish M-Score | -3.46 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -29.5 | |||||
3-Year EBITDA Growth Rate | 57.8 | |||||
3-Year EPS without NRI Growth Rate | 54.1 | |||||
3-Year FCF Growth Rate | 52.5 | |||||
3-Year Book Growth Rate | -36 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.72 | |||||
9-Day RSI | 39.69 | |||||
14-Day RSI | 42.61 | |||||
6-1 Month Momentum % | -6.25 | |||||
12-1 Month Momentum % | 15.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.21 | |||||
Quick Ratio | 2.36 | |||||
Cash Ratio | 1.22 | |||||
Days Inventory | 129.08 | |||||
Days Sales Outstanding | 59.59 | |||||
Days Payable | 37.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.2 | |||||
Shareholder Yield % | -1.3 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 29.16 | |||||
Operating Margin % | -29.29 | |||||
Net Margin % | -30.1 | |||||
FCF Margin % | -6.53 | |||||
ROE % | -23.44 | |||||
ROA % | -19.03 | |||||
ROIC % | -27.93 | |||||
ROC (Joel Greenblatt) % | -33.74 | |||||
ROCE % | -22.65 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.66 | |||||
PB Ratio | 0.59 | |||||
Price-to-Tangible-Book | 0.59 | |||||
EV-to-EBIT | -1.26 | |||||
EV-to-EBITDA | -1.66 | |||||
EV-to-Forward-EBITDA | -12.13 | |||||
EV-to-Revenue | 0.37 | |||||
EV-to-Forward-Revenue | 0.29 | |||||
EV-to-FCF | -5.6 | |||||
Price-to-Net-Current-Asset-Value | 1.08 | |||||
Price-to-Net-Cash | 6.5 | |||||
Earnings Yield (Greenblatt) % | -79.37 | |||||
FCF Yield % | -9.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
MediPharm Labs Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 39.05 | ||
EPS (TTM) (C$) | -0.04 | ||
Beta | 1.19 | ||
Volatility % | 40.71 | ||
14-Day RSI | 42.61 | ||
14-Day ATR (C$) | 0.00582 | ||
20-Day SMA (C$) | 0.06975 | ||
12-1 Month Momentum % | 15.38 | ||
52-Week Range (C$) | 0.06 - 0.1 | ||
Shares Outstanding (Mil) | 411.12 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
MediPharm Labs Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
MediPharm Labs Corp Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
MediPharm Labs Corp Frequently Asked Questions
What is MediPharm Labs Corp(TSX:LABS)'s stock price today?
When is next earnings date of MediPharm Labs Corp(TSX:LABS)?
Does MediPharm Labs Corp(TSX:LABS) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |